BOULDER, Colo., April 30, 2018 /PRNewswire/ -- Array BioPharma Inc. ARRY will report financial results for the third quarter of fiscal 2018 and hold a conference call to discuss those results on Wednesday, May 9, 2018.  Ron Squarer, Chief Executive Officer, will lead the call.

Webcast, including Replay and Conference Call Slides:

https://edge.media-server.com/m6/p/s5fgkv2a

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics). For more information on Array, please go to www.arraybiopharma.com.

CONTACT:       

Array BioPharma

Andrea N. Flynn, Ph.D.

Senior Director, Investor Relations & Corporate Communications            

(303) 381-6600

ir@arraybiopharma.com

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2018-on-may-9-2018-300639125.html

SOURCE Array BioPharma Inc.